RecallRadar

FDA Drug recall D-0542-2025

Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg, 100 Capsules bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Naple…

On 2025-08-06 the FDA classified a Class II recall of Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg, 100 Capsules bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Naple… by Lupin Pharmaceuticals, citing labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0542-2025
ClassificationClass II
Statusterminated
Initiated2025-07-02
Published2025-08-06
Last updated2026-09-13 11:52 UTC
CompanyLupin Pharmaceuticals
DistributionUS

Product

Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg, 100 Capsules bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL, 34108, United States, Manufactured by: Lupin Limited, Goa 103 722, INDIA, NDC 68180-755-01.

Reason

Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027

Identifiers

ndc68180-755-01
ndc68180-755-02
ndc68180-755-03
ndc68180-756-01
ndc68180-756-02
ndc68180-756-03
ndc68180-459-01
ndc68180-459-02
ndc68180-459-03
ndc68180-472-01
ndc68180-472-02
ndc68180-472-03
ndc68180-463-01
ndc68180-463-02
ndc68180-463-03
ndc68180-473-01
ndc68180-473-02
ndc68180-473-03
ndc68180-759-01
ndc68180-759-02
ndc68180-759-03
ndc68180-760-01
ndc68180-760-02
ndc68180-760-03
ndc68180-757-01
ndc68180-757-02
ndc68180-757-03
ndc68180-758-01
ndc68180-758-02
ndc68180-758-03
code_infoLot GB01616, expiration 2/28/2027

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0542-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.